AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2866965 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 144 mg/day
Number of subjects: 14
Study 2866965 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg o.d. and 8 mg once weekly
Number of subjects: 14
Study 2866965 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol long-term therapy
Number of subjects: 14
Study 2866965 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol treatment withdrawal
Number of subjects: 14
Study 30755452 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 5 mg
Number of subjects: 415
Study 30755452 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 20 mg
Number of subjects: 415
Study 30755452 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 40 mg
Number of subjects: 415
Study 30755452 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg
Number of subjects: 415
Study 30755452 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 415
Study 30755452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 29412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 48
Study 29412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 48
Study 29412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 48
Study 29412077 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 48
Study 26547304 — intervention group
Group type: EXPERIMENTAL
Intervention: When Cancer Calls… (WCC…) video
Number of subjects: 1006
Study 26547304 — intervention group
Group type: COMPARATOR
Intervention: Control video on cancer nutrition and diet
Number of subjects: 1006
Study 25455834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic intervention (specific details not provided)
Number of subjects: 247
Study 22595104 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate applied during endodontic surgery (in liquid form on the root end, in clot form within the bone defect, and in liquid form over the suture).
Number of subjects: 36
Study 22595104 — intervention group
Group type: COMPARATOR
Intervention: Control group (modern endodontic surgical procedure without platelet concentrate).
Number of subjects: 36
Study 19195850 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 410
Study 19195850 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sessions on depression prevention
Number of subjects: 410
Study 19195850 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 410
Study 19195850 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BDI
Number of subjects: 410
Study 17487767 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery (with CPB)
Number of subjects: 34
Study 17487767 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (without CPB)
Number of subjects: 34
Study 14694250 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP) treatment
Number of subjects: 36
Study 14694250 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of CPAP treatment
Number of subjects: 36
Study 14694250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 11581607 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 53
Study 11581607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 9836209 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.25 mg.kg‐1
Number of subjects: 102
Study 9836209 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 102
Study 9836209 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.75 mg.kg‐1
Number of subjects: 102
Study 9836209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9836209 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1 and 0.75 mg.kg‐1
Number of subjects: 102
Study 8120268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 240
Study 8120268 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 240
Study 2223156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin combination therapy (30 mg daily)
Number of subjects: 238
Study 2223156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study 526384 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 2 mg/kg body weight
Number of subjects: 37
Study 526384 — intervention group
Group type: EXPERIMENTAL
Intervention: ergometrine 0.5 mg
Number of subjects: 37
Study 526384 — intervention group
Group type: EXPERIMENTAL
Intervention: intra-cervical 0.5% lignocaine 20 ml
Number of subjects: 37
Study 526384 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium thiopentone 4 mg/kg body weight
Number of subjects: 37
Study 526384 — intervention group
Group type: COMPARATOR
Intervention: sodium thiopentone
Number of subjects: 37
Study 526384 — intervention group
Group type: COMPARATOR
Intervention: i.v. ketamine
Number of subjects: 37
Study 30894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (0.01-20 mg/kg)
Number of subjects: 52
Study 30894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (5 or 10 mg/kg)
Number of subjects: 52
Study 30894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab
Number of subjects: 52
Study 30894455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 980
Study 28280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 980
Study 28280233 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 980
Study 28280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide score (weighted sum of concentrations of four ceramides)
Number of subjects: 980
Study 28280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of C16:0, C22:0, C24:0, and C24:1 ceramides
Number of subjects: 980
Study 25826373 — intervention group
Group type: EXPERIMENTAL
Intervention: unfermented whole grain rye crisp bread (uRCB)
Number of subjects: 23
Study 25826373 — intervention group
Group type: EXPERIMENTAL
Intervention: fermented whole grain rye crisp bread (RCB)
Number of subjects: 23
Study 25826373 — intervention group
Group type: COMPARATOR
Intervention: refined wheat crisp bread (WCB)
Number of subjects: 23
Study 23383171 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 96
Study 23383171 — intervention group
Group type: COMPARATOR
Intervention: Pre-ART
Number of subjects: 96
Study 23383171 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ART
Number of subjects: 96
Study 22177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 64
Study 22177431 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 64
Study 19961377 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthreads placed at the implant top (group A)
Number of subjects: 20
Study 19961377 — intervention group
Group type: COMPARATOR
Intervention: Microthreads placed 0.5 mm below the implant top (group B)
Number of subjects: 20
Study 19961377 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bone loss between groups A and B
Number of subjects: 20
Study 19961377 — intervention group
Group type: COMPARATOR
Intervention: Gingival parameters (modified plaque index and modified sulcus bleeding index)
Number of subjects: 20
Study 17085674 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin intervention
Number of subjects: 546
Study 17085674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 17085674 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant UGT1A6 alleles
Number of subjects: 546
Study 15101466 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 75
Study 15101466 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 11733800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent crossclamping of the aorta with ischemic preconditioning (2 crossclampings of 3min each with 2min reperfusion)
Number of subjects: 35
Study 11733800 — intervention group
Group type: COMPARATOR
Intervention: Intermittent crossclamping of the aorta without ischemic preconditioning (control group)
Number of subjects: 35
Study 9310536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 262
Study 7667706 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Number of subjects: 0
Study 7667706 — intervention group
Group type: COMPARATOR
Intervention: Unimmunized children
Number of subjects: 0
Study 3540212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 45 mg/kg/day as a continuous IV infusion for 28 days
Number of subjects: 30
Study 3540212 — intervention group
Group type: COMPARATOR
Intervention: No other therapy (Control)
Number of subjects: 30
Study 28823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving in controllable condition
Number of subjects: 128
Study 28823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination in controllable condition
Number of subjects: 128
Study 28823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination in uncontrollable condition
Number of subjects: 128
Study 28823180 — intervention group
Group type: COMPARATOR
Intervention: Problem solving in uncontrollable condition
Number of subjects: 128
Study 28579385 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF4 varnish
Number of subjects: 20
Study 28579385 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF varnish
Number of subjects: 20
Study 28579385 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 20
Study 26605707 — intervention group
Group type: EXPERIMENTAL
Intervention: Secured email message
Number of subjects: 14584
Study 26605707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed letter
Number of subjects: 14584
Study 26605707 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone message
Number of subjects: 14584
Study 26605707 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm (no outreach)
Number of subjects: 14584
Study 22533576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 891
Study 22533576 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT
Number of subjects: 891
Study 19846273 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 12
Study 19846273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18468871 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS trained with PCA; classification results: 96.87%, 98.43%, 98.43%.
Number of subjects: 129
Study 18468871 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS combined with weighted arithmetical mean; classification results: 98.43%, 100%, 100%.
Number of subjects: 129
Study 18468871 — intervention group
Group type: COMPARATOR
Intervention: ANN ensemble; classification results: 98.43%, 100%, 100%.
Number of subjects: 129
Study 15666120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etidronate (200 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Number of subjects: 44
Study 15666120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etidronate (400 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Number of subjects: 44
Study 15666120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with osteoactive drugs)
Number of subjects: 44
Study 12897639 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 15 mg/day for 3 weeks
Number of subjects: 10
Study 12897639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10526278 — intervention group
Group type: EXPERIMENTAL
Intervention: rGM-CSF
Number of subjects: 67
Study 10526278 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (idarubicin, methylprednisolone, high dose ara-C)
Number of subjects: 67
Study 8682147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml kg‐1 of Ringer acetate solution without glucose
Number of subjects: 40
Study 8682147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml kg‐1 of Ringer acetate solution with 0.5% glucose
Number of subjects: 40
Study 1880475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 7
Study 1880475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6295132 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (4 mile walk‐jog run program 3 times weekly)
Number of subjects: 20
Study 6295132 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran feeding (0.5 g/kg body weight)
Number of subjects: 20
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL
Number of subjects: 123
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL
Number of subjects: 123
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL
Number of subjects: 123
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL
Number of subjects: 123
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL
Number of subjects: 123
Study 30900607 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL
Number of subjects: 123
Study 29031935 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h face-to-face RESPECT mental health training programme
Number of subjects: 1966
Study 29031935 — intervention group
Group type: COMPARATOR
Intervention: Deferred training control group
Number of subjects: 1966
Study 25638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to feed (0 h)
Number of subjects: 480
Study 25638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed access to feed (24 h)
Number of subjects: 480
Study 25638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed access to feed (6 h)
Number of subjects: 480
Study 25638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed access to feed (12 h)
Number of subjects: 480
Study 25638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall oocyst shedding
Number of subjects: 480
Study 24327421 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stents (EES)
Number of subjects: 2853
Study 23008509 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA closure with the Watchman device
Number of subjects: 1273
Study 23008509 — intervention group
Group type: COMPARATOR
Intervention: Sustained anticoagulation (warfarin)
Number of subjects: 1273
Study 21029995 — intervention group
Group type: EXPERIMENTAL
Intervention: HighCPAP treatment
Number of subjects: 11
Study 21029995 — intervention group
Group type: EXPERIMENTAL
Intervention: LowCPAP treatment
Number of subjects: 11
Study 17512011 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone HCl 30 mg twice daily
Number of subjects: 20
Study 17512011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15775926 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating using Rocatec System (Group RS)
Number of subjects: 15
Study 15775926 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating using CoJet System (Group CS)
Number of subjects: 15
Study 15775926 — intervention group
Group type: COMPARATOR
Intervention: Airborne-particle abrasion with 110-microm Al2O3 (Group SB)
Number of subjects: 15
Study 12063520 — intervention group
Group type: COMPARATOR
Intervention: HFA-BDP (200 microg twice daily)
Number of subjects: 39
Study 12063520 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-SM (100 microg FP and 50 microg SM twice daily)
Number of subjects: 39
Study 12063520 — intervention group
Group type: COMPARATOR
Intervention: DPI-BDP (1000 microg twice daily for 4 weeks)
Number of subjects: 39
Study 12063520 — intervention group
Group type: COMPARATOR
Intervention: DPI-BDP
Number of subjects: 39
Study 12063520 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-SM and HFA-BDP
Number of subjects: 39
Study 9877478 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oxygen (L)
Number of subjects: 51
Study 9877478 — intervention group
Group type: COMPARATOR
Intervention: Concentrator (C/C)
Number of subjects: 51
Study 7634630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intraoperatively and 30 mg every 8 hours for 5 doses postoperatively
Number of subjects: 303
Study 7634630 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 303
Study 2224948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Nicardipine (250 mg of aspirin once daily plus 20 mg of nicardipine thrice daily, n = 170)
Number of subjects: 264
Study 2224948 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only (250 mg of aspirin once daily, n = 94)
Number of subjects: 264
Study 2224948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Nicardipine
Number of subjects: 264
Study 2224948 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 264
Study 346049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg orally for 2 days)
Number of subjects: 12
Study 346049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 346049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone with aspirin
Number of subjects: 12
Study 346049 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aspirin
Number of subjects: 12
Study 346049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 12
Study 31442303 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention (WLI)
Number of subjects: 32
Study 31442303 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 32
Study 31753045 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical messages (BMM)
Number of subjects: 179
Study 31753045 — intervention group
Group type: COMPARATOR
Intervention: Recommended messages (RCM)
Number of subjects: 179
Study 29354177 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized tomato extract (STE)
Number of subjects: 65
Study 29354177 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 65
Study 25941197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture (No. 2 braided nonabsorbable polyethylene terephthalate sutures)
Number of subjects: 48
Study 25941197 — intervention group
Group type: COMPARATOR
Intervention: Absorbable suture (braided absorbable polyglactin sutures)
Number of subjects: 48
Study 23876833 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib continuation (arm A, n=18)
Number of subjects: 33
Study 23876833 — intervention group
Group type: COMPARATOR
Intervention: Imatinib discontinuation (arm B, n=15)
Number of subjects: 33
Study 21707137 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group cognitive-behavioral (FGCB) intervention
Number of subjects: 111
Study 21707137 — intervention group
Group type: COMPARATOR
Intervention: Written information comparison condition
Number of subjects: 111
Study 19505878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg subcutaneously once daily
Number of subjects: 129
Study 19505878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16703633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic use
Number of subjects: 6
Study 12956886 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain Rate Imaging in patients with acute myocardial infarction
Number of subjects: 12
Study 12956886 — intervention group
Group type: COMPARATOR
Intervention: Strain Rate Imaging in normal subjects
Number of subjects: 12
Study 12956886 — intervention group
Group type: COMPARATOR
Intervention: Peak systolic strain rate
Number of subjects: 12
Study 12956886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid systolic strain rate and end systolic strain
Number of subjects: 12
Study 11103192 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with midazolam and ketamine
Number of subjects: 33
Study 11103192 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with alfentanil and etomidate
Number of subjects: 33
Study 11103192 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with propofol (in combination with alfentanil or ketamine)
Number of subjects: 33
Study 11103192 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 50% nitrous oxide
Number of subjects: 33
Study 8922801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg p.o. t.i.d.)
Number of subjects: 182
Study 8922801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 8922801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 182
Study 1303075 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% w/w tea tree oil cream
Number of subjects: 104
Study 1303075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tolnaftate cream
Number of subjects: 104
Study 1303075 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 104
Study 3989740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning experiences
Number of subjects: 30
Study 3989740 — intervention group
Group type: COMPARATOR
Intervention: Individualistic learning experiences
Number of subjects: 30
Study 28677942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's fibular repositioning taping
Number of subjects: 16
Study 28677942 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 16
Study 27271264 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (n=15; 54±2 years)
Number of subjects: 30
Study 27271264 — intervention group
Group type: COMPARATOR
Intervention: Control (n=15; 49±2 years)
Number of subjects: 30